Erbin interacts with Sema4C and inhibits Sema4C-induced epithelial-mesenchymal transition in HK2 cells
- PMID: 24142719
- DOI: 10.1007/s11596-013-1179-7
Erbin interacts with Sema4C and inhibits Sema4C-induced epithelial-mesenchymal transition in HK2 cells
Abstract
Erbin, a member of Leucine-rich repeat and PDZ-containing protein family, was found to inhibit TGF-β-induced epithelial-mesenchymal transition (EMT) in our previous study. However, the mechanism of Erbin in regulating EMT is unclear. Semaphorin protein Sema4C, with PDZ binding site at C-terminal has been recognized as a positive regulator of EMT. Here, we aimed to examine the interaction between Erbin and Sema4C. HK2 cells were treated with TGF-β1, or transfected with Erbin and (or) Sema4C. Interaction of Erbin and Sema4C was identified by immunoprecipitation. RT-PCR was used to detect the expression of Erbin and Sema4C at mRNA level after transfection. The expression levels of Erbin, Sema4C, and markers of EMT were measured by using Western blotting or ELISA. After HK2 cells were stimulated with 10 ng/mL TGF-β1 for 72 h, the protein expression levels of Erbin and Sema4C were both up-regulated, and immunoprecipitation results showed Erbin interacted with Sema4C in HK2 cells both at endogenous and exogenous levels. Furthermore, overexpression of Sema4C suppressed E-cadherin, induced vimentin and promoted fibronectin secretion, indicating Sema4C promotes the process of EMT. However, HK2 cells overexpressing Erbin were resistant to Sema4C-induced EMT. In contrast, Erbin specific siRNA promoted EMT induced by Sema4C. Taken together, these results suggest that Erbin can interact with Sema4C, and co-expression of Erbin blocks the process of Sema4C-induced EMT.
Similar articles
-
MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.J Cell Mol Med. 2015 Dec;19(12):2793-805. doi: 10.1111/jcmm.12666. Epub 2015 Aug 18. J Cell Mol Med. 2015. PMID: 26283050 Free PMC article.
-
Role of Sema4C in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells.Nephrol Dial Transplant. 2011 Apr;26(4):1149-56. doi: 10.1093/ndt/gfq619. Epub 2010 Oct 19. Nephrol Dial Transplant. 2011. PMID: 20959347 Free PMC article.
-
Downregulation of SEMA4C Inhibit Epithelial-Mesenchymal Transition (EMT) and the Invasion and Metastasis of Cervical Cancer Cells via Inhibiting Transforming Growth Factor-beta 1 (TGF-β1)-Induced Hela cells p38 Mitogen-Activated Protein Kinase (MAPK) Activation.Med Sci Monit. 2020 Jan 17;26:e918123. doi: 10.12659/MSM.918123. Med Sci Monit. 2020. PMID: 31951596 Free PMC article.
-
Erbin inhibits TGF-β1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway.J Mol Med (Berl). 2012 May;90(5):563-74. doi: 10.1007/s00109-011-0833-4. Epub 2011 Nov 25. J Mol Med (Berl). 2012. PMID: 22116522
-
The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease.FEBS J. 2021 Feb;288(3):721-739. doi: 10.1111/febs.15450. Epub 2020 Jul 6. FEBS J. 2021. PMID: 32558243 Free PMC article. Review.
Cited by
-
MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.Oncotarget. 2015 Feb 20;6(5):3268-79. doi: 10.18632/oncotarget.3065. Oncotarget. 2015. PMID: 25605244 Free PMC article.
-
MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.J Cell Mol Med. 2015 Dec;19(12):2793-805. doi: 10.1111/jcmm.12666. Epub 2015 Aug 18. J Cell Mol Med. 2015. PMID: 26283050 Free PMC article.
-
miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.Cancer Sci. 2017 Jan;108(1):23-31. doi: 10.1111/cas.13104. Epub 2016 Dec 1. Cancer Sci. 2017. Retraction in: Cancer Sci. 2025 Jul;116(7):2047. doi: 10.1111/cas.70083. PMID: 27743413 Free PMC article. Retracted.
-
Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer.Front Cell Dev Biol. 2025 Mar 25;13:1544310. doi: 10.3389/fcell.2025.1544310. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40201201 Free PMC article. Review.
-
Sema4C modulates the migration of primary tumor-associated lymphatic endothelial cells via an ERK-mediated pathway.Exp Ther Med. 2021 Oct;22(4):1102. doi: 10.3892/etm.2021.10535. Epub 2021 Aug 2. Exp Ther Med. 2021. PMID: 34504556 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources